Solana Company Q4 FY2021 Earnings Call

· Earnings call transcript and AI-powered summary

Financial Performance
  • Q4 2021 Revenue: $258,000 (up from $191,000 in Q4 2020, a 35% YoY increase).
  • Sequential Growth: Revenue more than doubled relative to Q3 2021, with a 149% increase in product sales.
  • Gross Profit: $129,000 (compared to a gross loss of $10,000 in Q4 2020).
  • Operating Expenses: $4.2 million (up from $3.0 million in Q4 2020, mainly due to ramp-up costs ahead of U.S. commercial launch).
  • Net Loss: $4.1 million, or $1.31 per share (compared to $2.9 million, or $1.77 per share, in Q4 2020).
  • Cash Burn (FY 2021): $13.4 million (vs. $11.7 million in FY 2020).
  • Cash Position (as of Dec 31, 2021): $11 million with no debt, and $14.4 million additional availability via an equity line with Lincoln Park Capital.
  • Q1 2022 Outlook: Expecting revenue between $150,000 and $170,000 (approximately double Q1 2021's revenue). All revenue in Q1 expected to be from Canada.
Business & Commercial Highlights
  • U.S. Commercial Launch: PoNS therapy for MS launched in Q1 2022; first prescriptions received in early March. First shipments expected in April 2022.

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Operator: Ladies and gentlemen, thank you for standing by, and welcome to the Helius Medical Technologies Earnings Results Call. Please be advised that today's conference call is being recorded. I would now like to hand the conference over to your speaker today, Michelle Bilski. Thank you, please go ahead. Michelle Bilski: Thank you, Cherry. Welcome to the Q4 and full year 2021 earnings conference call for Helius Medical Technologies. This is Michelle Bilski of In-Site Communications, Investor Relations for Helius. With me on today's call are Dane Andreeff, Helius Medical's President and Chief Executive Officer; and Jeff Mathiesen, Chief Financial Officer. Please note that this call is being recorded, and access to the webcast can be obtained through the Investors section of the Helius website at www.heliusmedical.com. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on current expectations of management. These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including those identified in the risk factors section of most - of our most recent annual report on Form 10-K and quarterly report on Form 10-Q. Such factors may be updated from time to time in our filings with the SEC, which are available on our website. All statements made during this call are as of March 14, 2022. W

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional